HCW Biologics Inc. business relationships
Companies named in HCW Biologics Inc.’s 10-K filed 2026-03-31, and public companies whose annual reports name HCW Biologics Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 22 / 100 Top 2% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in HCW Biologics Inc.’s annual report 4
“The Company agreed to provide ImmunityBio with a right of first refusal to enter a licensing agreement for oncology indications for HCW9206.” SEC filing
“Under the terms of the Settlement Agreement, ImmunityBio will own the cell line and supply for HCW9218, and the parties agreed that within six months from the date of the Settlement Agreement they will enter into a supply agreement providing the Company with a continuing supply of HCW9218 molecules.” SEC filing
“As a result of the amendment to the license agreement with Wugen Inc. ("Wugen"), the Company has an opportunity, until May 28, 2026, to enter into a new license agreement based on using HCW9206 as a reagent in the manufacture of CAR-T products.” SEC filing
“We have a long-standing relationship with a contract manufacturing organization, EirGenix, Inc. ("EirGenix"), a third-party global contract development and cGMP manufacturer of biologics, for the manufacture of our internally-developed molecules.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.